Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 4

Results For "law"

207 News Found

Dr. Reddy’s secures first-mover advantage with FDA review of Orencia biosimilar
Clinical Trials | February 23, 2026

Dr. Reddy’s secures first-mover advantage with FDA review of Orencia biosimilar

BLA is based on a robust data package supporting similarity to Orencia (abatacept) IV for infusion through totality of evidence including pharmacokinetic (PK) data


Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal
Supply Chain | February 14, 2026

Citius Oncology expands LYMPHIR access across Europe via exclusive Uniphar deal

Under the deal, Uniphar will serve as LYMPHIR’s exclusive distribution partner across designated Western and Eastern European territories


India’s go-to diabetes test under scrutiny as new evidence flags major gaps
R&D | February 10, 2026

India’s go-to diabetes test under scrutiny as new evidence flags major gaps

The paper highlights how conditions common across India—including anemia, inherited hemoglobin disorders, and glucose-6-phosphate dehydrogenase (G6PD) deficiency—can significantly distort HbA1c readings


Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook
News | February 05, 2026

Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook

US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices


Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
News | January 30, 2026

Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience

The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio


Will Forte joins Teva Pharmaceuticals to shine spotlight on Huntington’s disease
News | January 29, 2026

Will Forte joins Teva Pharmaceuticals to shine spotlight on Huntington’s disease

HD causes cognitive, behavioral, and physical challenges, including involuntary movements known as HD chorea, which can disrupt daily life


Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation
News | January 17, 2026

Bayer welcomes the U.S. Supreme Court decision to review Durnell case in the Roundup litigation

Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy


Dr. Reddy’s launches first generic equivalent of extra-strength Pataday in US
News | January 14, 2026

Dr. Reddy’s launches first generic equivalent of extra-strength Pataday in US

Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% is an antihistamine eye drop, indicated for the temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair and dander


AstraZeneca names Rick R. Suarez as US President and Head of US BioPharmaceuticals Business Unit
People | January 10, 2026

AstraZeneca names Rick R. Suarez as US President and Head of US BioPharmaceuticals Business Unit

Appointment supports AstraZeneca’s $50 billion US investment and ambition to reach $80 billion in Total Revenue by 2030